Cargando…

Review: Pathogenesis of Helicobacter pylori infection

In this review, we shall focus on the last year progression understanding the pathogenesis of Helicobacter pylori infection in the light of recent data related to adaptation of H pylori to the harsh acidic environment in the stomach, colonization of gastric mucosa via interaction with mucin 5 (MUC5A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chmiela, Magdalena, Kupcinskas, Juozas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	The Year in Helicobacter. XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation & Cancer, Innsbruck, Austria, 5–7 September 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771490/ https://www.ncbi.nlm.nih.gov/pubmed/31486234 http://dx.doi.org/10.1111/hel.12638

Ejemplares similares

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
por: Oster, Paul, et al.
Publicado: (2022)

Helicobacter pylori infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis
por: Afsar, Md. Nure Alam, et al.
Publicado: (2020)

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention
por: Lee, Yi-Chia, et al.
Publicado: (2013)

A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro
por: Schlaermann, Philipp, et al.
Publicado: (2016)

A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis
por: Zhuang, Yuan, et al.
Publicado: (2015)

Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection
por: Sokolova, Olga, et al.
Publicado: (2013)

CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa
por: Cook, Katherine W, et al.
Publicado: (2014)

Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis
por: Cao, Qizhi, et al.
Publicado: (2015)

USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis
por: Costa, Lionel, et al.
Publicado: (2020)

Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments
por: Noto, Jennifer M, et al.
Publicado: (2018)

Helicobacter pylori
por: Harris, A. W. (Adam W.), 1963-
Publicado: (1996)

Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis
por: Chang, Yen-Lin, et al.
Publicado: (2020)

Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention
por: Zhou, Xian-Zhu, et al.
Publicado: (2023)

Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK
por: Pritchard, D. Mark, et al.
Publicado: (2021)

Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7
por: Yin, Yinfei, et al.
Publicado: (2010)

Assessment of Helicobacter pylori status by examination of gastric mucosal patterns: diagnostic accuracy of white-light endoscopy and narrow-band imaging
por: Glover, Ben, et al.
Publicado: (2021)

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
por: Liou, Jyh-Ming, et al.
Publicado: (2016)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
por: Suzuki, Sho, et al.
Publicado: (2020)

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines
por: Aebischer, T, et al.
Publicado: (2008)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients
por: Blaecher, C, et al.
Publicado: (2013)

Dietary habits and Helicobacter pylori infection: is there an association?
por: Soares, Giovana Alice Sampaio, et al.
Publicado: (2023)

Implications of the paradigm shift in management of Helicobacter pylori infections
por: Graham, David Y.
Publicado: (2023)

Therapeutic eradication choices in Helicobacter pylori infection in children
por: Manfredi, Marco, et al.
Publicado: (2023)

Update on the second-line treatment of Helicobacter pylori infection: a narrative review
por: Shih, Chih-An, et al.
Publicado: (2023)

Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts
por: Wang, Song-Wei, et al.
Publicado: (2023)

Helicobacter pylori in children: think before you kill the bug!
por: Ravikumara, M
Publicado: (2023)

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances
por: Shih, Chih-An, et al.
Publicado: (2022)

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
por: Moss, Steven F., et al.
Publicado: (2023)

Adequate amounts of probiotics increase the success rate of Helicobacter pylori eradication therapy in children
por: Kakiuchi, Toshihiko
Publicado: (2023)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
por: Zhao, Zhe, et al.
Publicado: (2022)

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial
por: Mei, Hao, et al.
Publicado: (2022)

High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis
por: Zhou, Ben-Gang, et al.
Publicado: (2023)

The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
por: He, Xiao-Jian, et al.
Publicado: (2023)

Changes in the gut microbiota composition and the plasma ghrelin level in patients with Helicobacter pylori-infected patients with eradication therapy
por: Yanagi, Hidetaka, et al.
Publicado: (2017)

Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer
por: Guo, Yang, et al.
Publicado: (2020)

Chemical transformation of xenobiotics by the human gut microbiota
por: Koppel, Nitzan, et al.
Publicado: (2018)

Molecular mimicry in Helicobacter pylori infections
por: Chmiela, Magdalena, et al.
Publicado: (2017)

Co-infection et surinfection bactérienne chez les patients hospitalisés pour COVID-19: une étude rétrospective monocentrique
por: Husain, M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mqthqjo48f8ag8hbffrp9i7pkh